Change in neuron specific enolase levels in out-of-hospital cardiopulmonary arrest survivors as a simple and useful tool to predict neurological prognosis.

Fosfopiruvato hidratasa Hipotermia inducida Hipoxia-isquemia cerebral Hypoxia-ischemia brain Induced hypothermia Muerte súbita extrahospitalaria Out-of-hospital cardiopulmonary arrest Phosphopyruvate hydratase Prognosis Pronóstico Supervivientes Survivors

Journal

Revista espanola de cardiologia (English ed.)
ISSN: 1885-5857
Titre abrégé: Rev Esp Cardiol (Engl Ed)
Pays: Spain
ID NLM: 101587954

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 03 07 2018
accepted: 18 01 2019
pubmed: 3 4 2019
medline: 20 9 2020
entrez: 3 4 2019
Statut: ppublish

Résumé

Neuron-specific enolase (NSE) is a prognostic marker in out-of-hospital cardiopulmonary arrest (OHCA) survivors treated with mild therapeutic hypothermia (MTH). The objectives were to analyze the correlation between dynamic changes in NSE and outcomes and to determine the measurement timing that best predicts neurological status. Multicenter cohort study including patients admitted after shockable rhythm OHCA and treated with MTH. Serum NSE was sampled at 2 different times and Δ-NSE (%) was calculated as 100 x (NSE2-NSE1)/NSE1. In-hospital mortality and neurological outcome, as assessed by the Cerebral Performance Category (CPC) scale, were evaluated during admission and after a 6-month follow-up. We included 166 patients admitted to 4 hospitals. In-hospital mortality was 31.9%. Almost 60% of patients had a good neurological recovery (CPC 1-2). On univariate and multivariate logistic regression analyses, an increase in NSE levels was associated with higher in-hospital mortality and worse CPC on discharge and after 6-months (P<.001). Positive Δ-NSE showed an OR=9.28 (95% CI 4.40-19.57) for mortality, OR=11.23 (95% CI 5.24-24.11) for CPC 3-5 at discharge and OR=11.14 (95% CI 5.05-24.55) for CPC 3-5 after 6-months' follow-up (P<.001). The first NSE measurement, conducted at 18 to 24hours, and the second measurement at 69 to 77hours after OHCA showed a high area under the curve in predicting CPC at discharge (0.9389 and 0.9909, respectively; 0.8096 for the whole cohort). Dynamic changes in NSE serum levels are good markers of hard clinical outcomes after an OHCA due to shockable rhythm in an MTH-treated cohort. NSE measurements at specific intervals after OHCA may predict events even more precisely.

Identifiants

pubmed: 30935900
pii: S1885-5857(19)30031-3
doi: 10.1016/j.rec.2019.01.007
pii:
doi:

Substances chimiques

Biomarkers 0
Phosphopyruvate Hydratase EC 4.2.1.11

Types de publication

Journal Article Multicenter Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

232-240

Informations de copyright

Copyright © 2019. Published by Elsevier España, S.L.U.

Auteurs

Agnès Rafecas (A)

Unidad de Críticos Cardiovasculares, Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jordi Bañeras (J)

Unidad de Críticos Cardiovasculares, Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Jordi Sans-Roselló (J)

Unidad de Cuidados Agudos e Intensivos Cardiovasculares, Departamento de Cardiología, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Barcelona, Spain.

José T Ortiz-Pérez (JT)

Instituto Clínico Cardiovascular, Hospital Clínic, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona, Spain.

Ferran Rueda-Sobella (F)

Departamento de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Estevo Santamarina (E)

Departamento de Neurología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Laia Milà (L)

Unidad de Críticos Cardiovasculares, Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Alessandro Sionis (A)

Unidad de Cuidados Agudos e Intensivos Cardiovasculares, Departamento de Cardiología, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute IIB-Sant Pau, Barcelona, Spain.

Carles Gaig (C)

Departamento de Neurología, Hospital Clínic, Barcelona, Spain.

Cosme García-García (C)

Departamento de Cardiología, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

José A Barrabés (JA)

Unidad de Críticos Cardiovasculares, Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

David García-Dorado (D)

Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Rosa-Maria Lidón (RM)

Unidad de Críticos Cardiovasculares, Departamento de Cardiología, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Centro de Investigación Biomédica En Red enfermedades Cardiovasculares (CIBERCV), Fundación Hospital Universitario Vall d'Hebron-Institut de Recerca (VHIR), Barcelona, Spain. Electronic address: rmlidon@vhebron.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH